Figure 3.
In vivo evaluation of G47Δ efficacy for human orthotopic tongue cancer models in athymic mice
(A). The experimental schedule is shown. (B and C) After 3 days of tumor implantation (B, SAS-GFP; C, HSC-3), G47Δ was intratumorally inoculated at a dose of 2 × 105 or 1 × 106 pfu, respectively. In both models, a single intratumoral injection with G47Δ significantly prolonged the survival at both doses. (D and E), After 5 (D, SAS-GFP) or 7 (E, HSC-3) days of tumor implantation, G47Δ was intratumorally inoculated at a dose of 2 × 105 or 1 × 106 pfu, respectively. In both models, a single intratumoral injection with G47Δ at a delayed timing significantly prolonged the survival. ∗∗p < 0.01; ∗∗∗p < 0.001 (log-rank test). (F) G47Δ at a low dose (2 × 105 pfu) or mock was inoculated intratumorally three times, 3, 6, and 9 days after tumor implantation (SAS-GFP), or G47Δ at a high dose (1 × 106 pfu) once 3 days after tumor implantation, and the survival was observed. Three-time injections with a low dose of G47Δ exhibited a significantly higher efficacy than a single injection with a high dose. ∗p < 0.05; ∗∗∗p < 0.001 (generalized Wilcoxon test). Arrows indicate the timings of G47Δ injection.